A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4) (REAL4)

• ClinicalTrials.gov Identifier: NCT03811535
• Recruitment Status: Active, not recruiting
• First Posted: January 22, 2019
• Results First Posted: August 4, 2023
• Last Update Posted: May 22, 2024
• Sponsor: Novo Nordisk A/S
• Information provided by (Responsible Party): Novo Nordisk A/S

Tracking Information

• First Submitted Date: January 18, 2019
• First Posted Date: January 22, 2019
• Results First Submitted Date: May 24, 2023
• Results First Posted Date: August 4, 2023
• Last Update Posted Date: May 22, 2024
• Actual Study Start Date: May 20, 2019
• Actual Primary Completion Date: November 10, 2021 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: May 24, 2023)

• Height Velocity: In-trial Observation Period [ Time Frame: From baseline (week 0) to visit 7 (week 52) ]
  Height velocity (HV) was derived from height measurements taken at baseline and Week 52 visit as: HV = (height at 52 weeks visit - height at baseline)/(time from baseline to 52 weeks visit in years). Data is reported for 'in-trial' observation period. In-trial observation period: from first administration and up until visit 7 or last trial contact, whichever comes first.
• Height Velocity: On-treatment Observation Period [ Time Frame: From baseline (week 0) to visit 7 (week 52) ]
  Height velocity was derived from height measurements taken at baseline and Week 52 visit as: HV = (height at 52 weeks visit - height at baseline)/(time from baseline to 52 weeks visit in years). Data is reported for 'on-treatment' observation period. On-treatment observation period: from first administration and up until last trial contact, visit 7 or 14 days after last administration, whichever comes first.

Original Primary Outcome Measures (submitted: January 18, 2019)

Height velocity [ Time Frame: Week 0-52 ]

Height velocity (HV) is measured in cm/year. HV = (height at 52 weeks visit - height at baseline)/(time from baseline to 52 weeks visit in years).

Current Secondary Outcome Measures (submitted: July 14, 2023)

• Change in Bone Age [ Time Frame: Baseline (week -2), week 52 ]
  Change from baseline (week -2) in bone age at week 52 is presented. X-ray images of left hand and wrist for bone age assessment according to the Greulich and Pyle atlas were taken. In-trial observation period: from first administration and up until visit 7 or last trial contact, whichever comes first.
• Change in Height Standard Deviation Score (HSDS) [ Time Frame: Baseline (week 0), week 52 ]
  Change from baseline (week 0) in HSDS at week 52 is presented. HSDS was derived using Centre for Disease Control and Prevention (CDC) standards. The range for HSDS was -10 to +10. Negative scores indicated a height below the mean height for a child with the same age and gender, whereas positive scores indicated a height above the mean height for a child with the same age and gender. Positive value in change from baseline in HSDS indicated that HSDS was better than baseline HSDS. In-trial observation period: from first administration and up until visit 7 or last trial contact, whichever comes first.
• Change in Height Velocity Standard Deviation Score (HV SDS) [ Time Frame: Baseline (week 0), week 52 ]
  Change from baseline (week 0) in HV SDS at week 52 is presented. HV SDS was calculated using the formula: HV SDS = (height velocity - mean)/standard deviation (SD), where height velocity was the height velocity variable measured, mean and SD of height velocity by gender and age for the reference population. The range for HV SDS was -10 to +10. Negative scores indicated a height velocity below the mean height velocity for a child with the same age and gender, whereas positive scores indicated a height velocity above the mean height velocity for a child with the same age and gender. Positive value in change from baseline in HV SDS indicated that HV SDS was better than baseline HV SDS. In-trial observation period: from first administration and up until visit 7 or last trial contact, whichever comes first.
• Change in Fasting Plasma Glucose (FPG) at Week 52 [ Time Frame: Baseline (week -2), week 52 ]
  Change from baseline (week -2) in FPG at week 52 is presented.
• Change in FPG at Week 104 [ Time Frame: Baseline (week -2), week 104 ]
• Change in FPG at Week 156 [ Time Frame: Baseline (week -2), week 156 ]
• Change in FPG at Week 208 [ Time Frame: Baseline (week -2), week 208 ]
• Change in Homeostatic Model Assessment Steady State Beta Cell Function (HOMA-B) at Week 52 [ Time Frame: Baseline (week -2), week 52 ]
  Change from baseline (week -2) in HOMA-B at week 52 is presented. HOMA-B is a measure of the beta cell function and was calculated as follows: HOMA-B = (20 * fasting insulin (picomoles per liter [pmol/L]) * 1/6(microunit per milliliter [µU/mL]))/ FPG(mmol/L)-3.5). Negative change from baseline in HOMA-B indicated a worse outcome.
• Change in HOMA-B at Week 104 [ Time Frame: Baseline (week -2), week 104 ]
• Change in HOMA-B at Week 156 [ Time Frame: Baseline (week -2), week 156 ]
• Change in HOMA-B at Week 208 [ Time Frame: Baseline (week -2), week 208 ]
• Change in Homeostatic Model Assessment Insulin Resistance (HOMA-IR) at Week 52 [ Time Frame: Baseline (week -2), week 52 ]
  Change from baseline (week -2) in HOMA-IR at week 52 is presented. HOMA-IR is an evaluation of the insulin resistance and was calculated as HOMA-IR = fasting insulin (pmol/L) * 1/6(µU/mL) * FPG(mmol/L) / 22.5. Positive change from baseline in HOMA-IR indicated a worse outcome.
• Change in HOMA-IR at Week 104 [ Time Frame: Baseline (week -2), week 104 ]
• Change in HOMA-IR at Week 156 [ Time Frame: Baseline (week -2), week 156 ]
• Change in HOMA-IR at Week 208 [ Time Frame: Baseline (week -2), week 208 ]
• Change in Glycated Haemoglobin (HbA1c) at Week 52 [ Time Frame: Baseline (week -2), week 52 ]
  Change from baseline (week -2) in HbA1c at week 52 is presented.
• Change in HbA1c at Week 104 [ Time Frame: Baseline (week -2), week 104 ]
• Change in HbA1c at Week 156 [ Time Frame: Baseline (week -2), week 156 ]
• Change in HbA1c at Week 208 [ Time Frame: Baseline (week -2), week 208 ]
• Change in Insulin-like Growth Factor I (IGF-I) Standard Deviation Score (SDS) at Week 52 [ Time Frame: Baseline (week 0), week 52 ]
  Change from baseline (week 0) in IGF-I SDS at week 52 is presented. The range for IGF-I SDS was from -10 to +10. Negative scores indicated a IGF-I below the mean IGF-I for a child with the same age and gender, whereas positive scores indicated a IGF-I above the mean IGF-I for a child with the same age and gender. For participants with low IGF-I SDS at baseline, a positive change from baseline in IGF-I SDS indicated a better outcome. Data is reported for 'in-trial' observation period. In-trial observation period: from first administration and up until visit 7 or last trial contact, whichever comes first.
• Change in IGF-I SDS at Week 104 [ Time Frame: Baseline (week 0), week 104 ]
• Change in IGF-I SDS at Week 156 [ Time Frame: Baseline (week 0), week 156 ]
• Change in IGF-I SDS at Week 208 [ Time Frame: Baseline (week 0), week 208 ]
• Change in Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) Standard Deviation Score (SDS) at Week 52 [ Time Frame: Baseline (week 0), week 52 ]
  Change from baseline (week 0) in IGFBP-3 SDS at week 52 is presented. The range for IGFBP-3 SDS was from -10 to +10. Negative scores indicated a IGFBP-3 below the mean IGFBP-3 for a child with the same age and gender, whereas positive scores indicated a IGFBP-3 above the mean IGFBP-3 for a child with the same age and gender. For participants with low IGFBP-3 SDS at baseline, a positive change from baseline in IGFBP-3 SDS indicated a better outcome. Data is reported for 'in-trial' observation period. In-trial observation period: from first administration and up until visit 7 or last trial contact, whichever comes first.
• Change in IGFBP-3 SDS at Week 104 [ Time Frame: Baseline (week 0), week 104 ]
• Change in IGFBP-3 SDS at Week 156 [ Time Frame: Baseline (week 0), week 156 ]
• Change in IGFBP-3 SDS at Week 208 [ Time Frame: Baseline (week 0), week 208 ]

Original Secondary Outcome Measures (submitted: January 18, 2019)

• Change in bone age: Week 52 [ Time Frame: Week -2, Week 52 ]
  Measured in years.
• Change in bone age: Week 104 [ Time Frame: Week -2, Week 104 ]
  Measured in years.
• Change in bone age: Week 156 [ Time Frame: Week -2, Week 156 ]
  Measured in years.
• Change in bone age: Week 208 [ Time Frame: Week -2, Week 208 ]
  Measured in years.
• Change in height standard deviation score (SDS): Week 52 [ Time Frame: Week 0, Week 52 ]
  Measured in scores (-10 to +10). Height SDS will be derived using Centre for Disease Control and Prevention (CDC) standards.
• Change in Height SDS: Week 104 [ Time Frame: Week 0, Week 104 ]
  Measured in scores (-10 to +10). Height SDS will be derived using CDC standards.
• Change in Height SDS: Week 156 [ Time Frame: Week 0, Week 156 ]
  Measured in scores (-10 to +10). Height SDS will be derived using CDC standards.
• Change in Height SDS: Week 208 [ Time Frame: Week 0, Week 208 ]
  Measured in scores (-10 to +10). Height SDS will be derived using CDC standards.
• Change in height velocity standard deviation score (HV SDS): Week 52 [ Time Frame: Week 0, Week 52 ]
  Measured in scores (-10 to +10). HV SDS will be derived using Prader standards as reference data.
• Change in HV SDS: Week 104 [ Time Frame: Week 0, Week 104 ]
  Measured in scores (-10 to +10). HV SDS will be derived using Prader standards as reference data.
• Change in HV SDS: Week 156 [ Time Frame: Week 0, Week 156 ]
  Measured in scores (-10 to +10). HV SDS will be derived using Prader standards as reference data.
• Change in HV SDS: Week 208 [ Time Frame: Week 0, Week 208 ]
  Measured in scores (-10 to +10). HV SDS will be derived using Prader standards as reference data.
• Change in fasting plasma glucose (FPG): Week 52 [ Time Frame: Week -2, Week 52 ]
  Measured in mmol/L.
• Change in FPG: Week 104 [ Time Frame: Week -2, Week 104 ]
  Measured in mmol/L.
• Change in FPG: Week 156 [ Time Frame: Week -2, Week 156 ]
  Measured in mmol/L.
• Change in FPG: Week 208 [ Time Frame: Week -2, Week 208 ]
  Measured in mmol/L.
• Change in homeostatic model assessment (HOMA): Week 52 [ Time Frame: Week -2, Week 52 ]
  Measured in percentage.
• Change in HOMA: Week 104 [ Time Frame: Week -2, Week 104 ]
  Measured in percentage.
• Change in HOMA: Week 156 [ Time Frame: Week -2, Week 156 ]
  Measured in percentage.
• Change in HOMA: Week 208 [ Time Frame: Week -2, Week 208 ]
  Measured in percentage.
• Change in glycated haemoglobin (HbA1c): Week 52 [ Time Frame: Week -2, Week 52 ]
  Measured in percentage
• Change in HbA1c: Week 104 [ Time Frame: Week -2, Week 104 ]
  Measured in percentage
• Change in HbA1c: Week 156 [ Time Frame: Week -2, Week 156 ]
  Measured in percentage
• Change in HbA1c: Week 208 [ Time Frame: Week -2, Week 208 ]
  Measured in percentage
• Change in insulin-like growth factor I (IGF-I) SDS: Week 52 [ Time Frame: Week 0, Week 52 ]
  Measured in scores (-10 to +10).
• Change in IGF-I SDS: Week 104 [ Time Frame: Week 0, Week 104 ]
  Measured in scores (-10 to +10).
• Change in IGF-I SDS: Week 156 [ Time Frame: Week 0, Week 156 ]
  Measured in scores (-10 to +10).
• Change in IGF-I SDS: Week 208 [ Time Frame: Week 0, Week 208 ]
  Measured in scores (-10 to +10).
• Change in insulin-like growth factor binding protein 3 (IGFBP-3) SDS: Week 52 [ Time Frame: Week 0, Week 52 ]
  Measured in scores (-10 to +10).
• Change in IGFBP-3 SDS: Week 104 [ Time Frame: Week 0, Week 104 ]
  Measured in scores (-10 to +10).
• Change in IGFBP-3 SDS: Week 156 [ Time Frame: Week 0, Week 156 ]
  Measured in scores (-10 to +10).
• Change in IGFBP-3 SDS: Week 208 [ Time Frame: Week 0, Week 208 ]
  Measured in scores (-10 to +10).

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)
• Official Title: A Trial Comparing the Effect and Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® in Children With Growth Hormone Deficiency
• Brief Summary: The study compares 2 medicines for children who do not have enough hormone to grow: somapacitan given once a week (a new medicine) and Norditropin® given once a day (the medicine doctors can already prescribe). Researchers will test to see how well somapacitan works. The study will also test if somapacitan is safe. Participants will either get somapacitan or Norditropin® - which treatment participants get, is decided by chance. Both participants and the study doctor will know which treatment participants get. The study will last for 4 years. Participants will attend 19 clinic visits and have 1 phone call with the study doctor.
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 3

Study Design

Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Participants will receive either somapacitan once weekly or Norditropin® once daily for 52 weeks (main trial period). All participants completing the main trial period will receive somapacitan weekly for 3 years (extension trial period).

Masking: None (Open Label)
Primary Purpose: Treatment

• Condition: Growth Hormone Deficiency in Children

Intervention

• Drug: Somapacitan
  Somapacitan will be administered subcutaneously (s.c.; under the skin) once weekly by PDS290 pen-injector. Somapacitan can be injected any time during the once weekly dosing day. The dose will be calculated based on the subject's current body weight.
• Drug: Norditropin®
  Norditropin® will be administered s.c. once daily by FlexPro® pen-injector. Norditropin® should be injected daily in the evening. The dose will be calculated based on the subject's current body weight.

Study Arms

• Experimental: Somapacitan weekly
  Participants will receive somapacitan weekly for 52 weeks (main trial period). Participants completing the main trial period in both the treatment arms ('Somapacitan weekly' and 'Norditropin® daily') will receive somapacitan weekly for 3 years (extension trial period).
  Intervention: Drug: Somapacitan
• Active Comparator: Norditropin® daily
  Participants will receive Norditropin® daily for 52 weeks (main trial period).
  Intervention: Drug: Norditropin®

• Publications *: Miller BS, Blair JC, Rasmussen MH, Maniatis A, Kildemoes RJ, Mori J, Polak M, Bang RB, Bottcher V, Stagi S, Horikawa R. Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial. J Clin Endocrinol Metab. 2022 Nov 25;107(12):3378-3388. doi: 10.1210/clinem/dgac513.

Recruitment Information

• Recruitment Status: Active, not recruiting
• Actual Enrollment (submitted: January 22, 2021): 200
• Original Estimated Enrollment (submitted: January 18, 2019): 188
• Estimated Study Completion Date: September 30, 2025
• Actual Primary Completion Date: November 10, 2021 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Prepubertal children: a) Boys: Age more than or equal to 2 years and 26 weeks and less than 11.0 years at screening. Testis volume less than 4 ml. b) Girls: Age more than or equal to 2 years and 26 weeks and less than 10.0 years at screening. Tanner stage 1 for breast development (no palpable glandular breast tissue)
• Confirmed diagnosis of growth hormone deficiency determined by two different growth hormone stimulation tests performed within 12 months prior to randomisation, defined as a peak growth hormone level of less than or equal to 10.0 ng/ml using the World Health Organisation (WHO) International Somatropin 98/574 standard
• Impaired height defined as at least 2.0 standard deviations below the mean height for chronological age and gender at screening according to the standards of Center for Disease Control and Prevention
• Impaired height velocity, defined as annualised height velocity below the 25th percentile for chronological age and gender according to the standards of Prader calculated over a time span of minimum 6 months and maximum 18 months prior to screening
• Insulin-like Growth Factor-I (IGF-I) less than -1.0 SDS at screening, compared to age and gender normalized range measured at central laboratory
• No prior exposure to growth hormone therapy or IGF-I treatment

Exclusion Criteria:

• Any known or suspected clinically significant abnormality likely to affect growth or the ability to evaluate growth with standing height measurements
• Current inflammatory diseases requiring systemic corticosteroid treatment for longer than 2 consecutive weeks within the last 3 months prior to screening
• Children requiring inhaled glucocorticoid therapy at a dose of greater than 400 μg/day of inhaled budesonide or equivalents for longer than 4 consecutive weeks within the last 12 months prior to screening
• Diagnosis of attention deficit hyperactivity disorder
• Concomitant administration of other treatments that may have an effect on growth, e.g. but not limited to methylphenidate for treatment of attention deficit hyperactivity disorder
• Prior history or presence of malignancy including intracranial tumours

Sex/Gender

• Sexes Eligible for Study: All

• Ages: up to 11 Years (Child)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Algeria, Austria, Canada, France, Germany, India, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Poland, Russian Federation, Serbia, Slovenia, Spain, Switzerland, Thailand, Ukraine, United Kingdom, United States
• Removed Location Countries: Denmark, Estonia, Hungary, Norway

Administrative Information

• NCT Number: NCT03811535
• Other Study ID Numbers: NN8640-4263; U1111-1207-9691 ( Other Identifier: World Health Organization (WHO) ); 2018-000231-27 ( Other Identifier: European Medicines Agency (EudraCT) ); JapicCTI-194773 ( Registry Identifier: JAPIC (Japan) )
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: Yes
• Plan Description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
• URL: https://www.novonordisk-trials.com

• Current Responsible Party: Novo Nordisk A/S
• Original Responsible Party: Same as current
• Current Study Sponsor: Novo Nordisk A/S
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Study Director: Clinical Transparency (dept. 2834); Novo Nordisk A/S

• PRS Account: Novo Nordisk A/S
• Verification Date: May 2024